HOUSTON, TX – FEBRUARY 22, 2023 – Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced today successful treatment of the first patients in the A PRIORI (Aortix therapy for Perioperative ReductIon Of Renal Injury) pilot trial to evaluate the performance of its Aortix™ percutaneous mechanical circulatory support (pMCS) device in preventing acute kidney injury (AKI) during cardiac surgery, a common and serious complication that impacts approximately 30% of patients.1 The A PRIORI study will enroll up to 50 patients across four clinical sites in Australia: Royal Adelaide Hospital, Monash Health, Princess Alexandra Hospital, and Macquarie University.
“We are thrilled to be the first center in the world to provide Aortix pump therapy during a cardiac surgery with the goal of reducing the risk of AKI,” said…